Monocytes from patients with myelodysplastic syndromes are more resistant to inhibition by thalidomide.
Stef
S
Meers
Louis
L
Boon
Gregor
G
Verhoef
Michel
M
Delforge
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D002478:Cells, Cultured; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000276:immunology; D013792:Thalidomide / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide